The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

With nearly half of Americans saying weight loss is a goal for them, it’s no wonder that interest in GLP-1 medications has ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Klarity - Weight Loss Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.